Cocrystal Pharma, Inc.

Equities

COCP

US19188J4094

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
2.07 ^USD	-2.81%		-1.43%	+20.20%

05-01	Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects	CI
03-28	Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Cocrystal Pharma, Inc. Announces Resignation of Curtis Dale as Interim Chief Financial Officer

January 30, 2017 at 09:32 pm

Cocrystal Pharma, Inc. announced that Curtis Dale, Interim Chief Financial Officer, tendered his resignation effective immediately on January 24, 2017. The company has initiated a search for a qualified replacement.

Latest news about Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects	05-01	CI
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates	01-04	CI
Top Premarket Gainers	12-07	MT
Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A	12-06	CI
Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast	11-29	CI
Cocrystal Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus	28/09/23	CI
Cocrystal Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Cocrystal Pharma Files $150 Million Mixed Shelf	25/05/23	MT
HC Wainwright Adjusts Cocrystal Pharma's Price Target to $12 From $35, Keeps Buy Rating	24/05/23	MT
Cocrystal Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Cocrystal Pharma Files $150 Million Mixed Shelf	15/05/23	MT
Cocrystal Pharma, Inc. Appoints Fred Hassan to Its Board of Directors	24/04/23	CI
Cocrystal Pharma, Inc. announced that it has received $4.000002 million in funding from Frost Gamma Investments Trust	09/04/23	CI
Insider Buy: Cocrystal Pharma	06/04/23	MT
Cocrystal Pharma, Inc. announced that it expects to receive $4.000002 million in funding from Frost Gamma Investments Trust and other investor	03/04/23	CI
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23	CI
HC Wainwright Adjusts Price Target on Cocrystal Pharma to $35 From $42, Maintains Buy Rating	24/01/23	MT
Cocrystal Pharma Says Study of Antiviral Treatment for Influenza A Showed Mild Adverse Events	19/12/22	MT
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A	19/12/22	CI
CoCrystal Pharma, Inc. Highlights Progress with CC-42344 as Potential Oral Treatment for Pandemic and Seasonal Influenza A at World Antiviral Congress 2022	01/12/22	CI
Cocrystal Pharma, Inc. Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A	17/11/22	CI
Cocrystal Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
HC Wainwright Adjusts Price Target on Cocrystal Pharma to $42 From $48, Maintains Buy Rating	07/11/22	MT

Chart Cocrystal Pharma, Inc.

Duration

Period

More charts

Company Profile

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.

Sector

Biotechnology & Medical Research

Calendar

25/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.13 USD

Average target price

8.667 USD

Spread / Average Target

+306.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
COCRYSTAL PHARMA, INC.	+20.20%	21.67M
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B

Bio Therapeutic Drugs